Amplifica Announces First-in-Human Study Initiated
Amplifica’s AMP-303 safety and tolerability study targeting hair loss
Amplifica’s AMP-303 safety and tolerability study targeting hair loss
Exclusive Licensing Agreement Allows for Access to Promising Early-Stage
Exclusive Licensing Agreement Allows for Access to Promising Early-Stage ProteinSAN
SAN DIEGO, CA - Amplifica Holdings Group, Inc. (“Amplifica”),